117O Stereotactic body radiotherapy (SBRT) with pembrolizumab (pembro) for unresected stage I/II non-small cell lung cancer (NSCLC): The randomized, double-blind, phase III KEYNOTE-867 study
Andreas Pircher(Innsbruck Medical University), Szabolcs Soter(Országos Korányi Tbc és Pulmonológiai Intézet), Michael A. W. Eaton(Franciscan Health Indianapolis), G. Galffy(Országos Korányi Tbc és Pulmonológiai Intézet), D. Kowalski(The Maria Sklodowska-Curie National Research Institute of Oncology), Atsushi Hata(Kobe Medical Center), Abdhiel Bustamante-Navarrete(Vall d'Hebron Hospital Universitari), Nikolaj Frost(Humboldt-Universität zu Berlin), E. Levchenko(Institute of Oncology NN Petrov), Mariana P. Monteiro(Universidade de São Paulo), Anoop Haridass(Clatterbridge Cancer Centre NHS Foundation Trust), M. Bouchard(Centre Hospitalier Universitaire de Sherbrooke), M.V. Bluthgen(Hospital Alemán), M-J. Ahn(Samsung Medical Center), B.G.M. Hughes(Cancer Care Services), Amy C. Durham(University of Geneva), Yiquan Xu(Decision Sciences (United States)), Ayman Samkari(Merck & Co., Inc., Rahway, NJ, USA (United States)), A. Song(Merck & Co., Inc., Rahway, NJ, USA (United States)), Salma K. Jabbour(Rutgers, The State University of New Jersey)
Cited by 11Open Access
Abstract
Related Papers
No related papers found
Powered by citation graph analysis